{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"17.340","rs_stock_flag":false,"fiscal_year_end":"31 Dec 2024","hist_closedate":"25 Sep 2025","replication_method":null,"amt_os":"672,361,350","primaryexch":"HKEX","ric":"2256.HK","product_subtype":null,"db_updatetime":"26 Sep 2025 18:38","mkt_cap_u":"B","am_u":"M","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":0.0446,"inline_upper_strike_price":"","sedol":"BMCP6L9","am":"82.17","iv":"","ew_strike":"","as":"16.950","geographic_focus":null,"incorpin":"Cayman Islands","etp_baseCur":null,"ew_amt_os":"","bd":"16.880","registrar":"Computershare Hong Kong Investor Services Ltd.","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"1,000","update_time":"2025-09-26 10:38:37.0","lo52":"3.120","shares_issued_date":"31 Aug 2025","premium":"","strike_price_ccy":null,"yield":"","vo_u":"M","base_currency":null,"coupon":"","expiry_date":"","chairman":"Xu Yao-Chang","underlying_ric":"2256.HK","hi52":"18.920","issuer_name":"Abbisko Cayman Ltd. - B","h_share_flag":false,"ew_sub_per_from":"","div_yield":"","interest_payment_date":"-","updatetime":"26 Sep 2025 16:08","aum_date":"","lo":"16.510","mkt_cap":"11.39","f_aum_hkd":null,"ew_sub_per_to":"","ls":"16.950","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"Healthcare - Pharmaceuticals & Biotechnology","ew_desc":null,"inception_date":"","nc":"-0.280","aum":"","issued_shares_class_B":null,"vo":"4.83","secondary_listing_flag":false,"listing_date":"13 Oct 2021","issued_shares_class_A":null,"as_at_label":"as at","ew_amt_os_dat":"","nm":"Abbisko Cayman Ltd. - B","nm_s":"ABBISKO-B","sym":"2256","inline_lower_strike_price":"","listing_category":"Primary Listing","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.010","strike_price":"","summary":"Abbisko Cayman Ltd is a research and development-driven, clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The Company's clinical-stage drug candidates include ABSK011 inhibitors, ABSK091 inhibitors, ABSK021 inhibitors and ABSK081 antagonists. The Company's selective preclinical stage drug candidates include ABSK043 inhibitors, ABSK061 inhibitors, ABSK121 inhibitors, ABSK012 inhibitors, ABSK111 inhibitors, ABSK071 inhibitors, ABSK051 inhibitors, and ABSK031 antagonists.","op":"17.300","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"Biotechnology","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"40th Floor<br/>Dah Sing Financial Centre<br/>No. 248 Queen's Road East<br/>Wanchai, Hong Kong","pc":"-1.63","days_to_expiry":null,"underlying_code":null,"pe":"359.87","eps_ccy":"RMB","hdr":false,"launch_date":"","hc":"17.230","isin":"KYG0028A1085","moneyness":""}},"qid":"1758890175491"}
